Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
11:37am, Friday, 15'th Nov 2024
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Partic
Where Will CRISPR Therapeutics Be in 3 Years?
05:45am, Friday, 15'th Nov 2024
Where Will CRISPR Therapeutics Be in 3 Years?
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
08:30am, Thursday, 14'th Nov 2024
ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea
3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029
06:30am, Wednesday, 13'th Nov 2024
These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
12:54pm, Monday, 11'th Nov 2024
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
01:22pm, Friday, 08'th Nov 2024
The rock star fund investor made a lot of big moves on Thursday.
Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?
10:55am, Wednesday, 06'th Nov 2024
The mean of analysts' price targets for CRISPR Therapeutics (CRSP) points to a 62.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates
09:31am, Wednesday, 06'th Nov 2024
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
11:10am, Tuesday, 05'th Nov 2024
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.41 per share a year ago.
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
09:01am, Tuesday, 05'th Nov 2024
-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada-
CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average
10:35am, Monday, 04'th Nov 2024
CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CRSP crossed above the 20-day moving average, s
CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average
10:31am, Monday, 04'th Nov 2024
After reaching an important support level, CRISPR Therapeutics AG (CRSP) could be a good stock pick from a technical perspective. CRSP surpassed resistance at the 50-day moving average, suggesting a s
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
10:00am, Saturday, 02'nd Nov 2024
It won't be able to be profitable without hitting its targets for both of these figures.
12 High-Growth Stocks That Could Deliver Parabolic Returns
10:00am, Monday, 28'th Oct 2024
These 12 innovative companies could deliver exponential returns over the next quarter century.
CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?
09:36am, Monday, 28'th Oct 2024
On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.
